The U.S. Department of Health and Human Services has established a Long COVID consortium as a national priority for 2025 and 2026, signaling renewed federal focus on a chronic condition that continues to affect millions of Americans and for which no therapy has yet been approved.
Led at the secretary level by Robert F. Kennedy Jr., the consortium brings together a broad set of voices, including senators, patients, clinicians and researchers, and convened a roundtable to shape a coordinated national response. The effort is organized around several focus areas.
- Centering patient perspectives and lived experience in policy and research.
- Developing clearer clinical care protocols for diagnosis and management.
- Accelerating treatment research toward disease-modifying therapies.
- Advancing diagnostic innovation so the condition can be identified and tracked accurately.
Why this matters for TechImmune
A federal commitment of this scale validates the urgency that has driven TechImmune since its founding. The consortium's emphasis on treatment research and diagnostic innovation aligns directly with the company's mission: to deliver the first disease-modifying immunotherapy for Long COVID by clearing persistent SARS-CoV-2 reservoirs and restoring functional anti-viral immunity.
As policymakers, clinicians and patients press for solutions, TechImmune is advancing a T-cell antigen platform toward IND-enabling studies, with the goal of bringing the first approved therapeutic intervention to a patient population that has waited far too long for one.
About TechImmune, Inc.
TechImmune, Inc. is a preclinical-stage biotechnology company developing first-in-class T-cell immunotherapies that target the root cause of Long COVID and related coronavirus diseases. Founded in 2021 and headquartered in Irvine, California, the company is advancing a platform exclusively licensed from the University of California toward IND-enabling studies and first-in-human trials.